Thursday, 19 November 2026 / 9 Jamadilakhir 1448H – The Ministry of Health would like to alert members of the public to two (2) types of Health products which has been tested by the Laboratory of Pharmacy Section, Department of Scientific Services, Ministry of Health and found to be adulterated with undeclared active pharmaceutical ingredients which are controlled under the Medicines Act, Chapter 285.
The affected health products are listed below:
No. | Name of product | Manufacturer | Adulterated with |
1. | Raja Penawar Resdung | NA | Chlorpheniramine, Betamethasone, Dexamethasone and Prednisolone. |
2. | Xuandi | NA | Acetaminophen |
The undeclared pharmaceutical ingredients found in these products may cause adverse effects and pose health risks to consumers, particularly when the products are used without appropriate medical supervision.
Chlorpheniramine is used to relieve allergy symptoms, and it may cause several adverse effects including drowsiness, dizziness, muscle weakness, decreased blood pressure, blurred vision, dry mouth, depression, and an irregular heartbeat
Unsupervised long-term consumption of potent corticosteroids such as Dexamethasone, Betamethasone and Prednisolone can cause an increase in blood glucose levels leading to diabetes, high blood pressure, cataract, muscular and bone disorders, and an increased risk of infections. Long term use of corticosteroids can also lead to Cushing’s syndrome which is characterized by a round face or ‘moon face’, and upper body obesity with thin limbs. Consumers who have taken high doses of steroids over a prolonged period of time may suffer from withdrawal symptoms when the steroids are discontinued abruptly. This includes fatigue, muscle and joint pain, fever, low blood sugar, low blood pressure and dehydration.
Acetaminophen or paracetamol is a medicine that can be used for pain relief and to reduce fever. However, health supplements adulterated with acetaminophen or paracetamol can lead to an overdose causing liver damage, kidney failure, coma and can result in death.
The Ministry of Health has not issued any approval for the importation for the sale of these products. Following this finding, these products are not allowed to be imported and sold in Brunei Darussalam.
Members of the public who have purchased or used these products are advised to stop taking them immediately. Anyone who feels unwell or experiences an undesirable reaction after them should consult a medical practitioner.
Members of the public are advised to consult a doctor or pharmacist before taking any health product. They should avoid purchasing or using products from unknown sources, particularly those sold on online platforms. Consumers should also exercise caution when considering product claims, especially those promising ‘instant results’ or ‘no side effects’.
Members of the public involved in the retail of these products (including online retail such as through Facebook, etc.) are hereby reminded that it is an offence under the Medicines Act, Chapter 285 to sell this product containing substances controlled under the said Act without appropriate licence where a compound fine may be imposed. Upon conviction, a person is liable to a fine not exceeding $5,000, imprisonment for a term not exceeding 2 years, or both.
The Ministry of Health also urges the public to report any of these products, or other suspected products, found in the market in Brunei Darussalam to the Compliance and Licensing Section, Department of Pharmaceutical Services. The Ministry of Health will continue to monitor these products in the marketplace to ensure public safety.
The Ministry of Health would also like to call upon the public for their cooperation to report to the Compliance and Licensing Section, Department of Pharmaceutical Services if any of this product or any dubious products are found on the market in this country. The Ministry of Health will continue to monitor these products in the marketplace to ensure public safety.
For further information, members of the public may contact the Compliance and Licensing Section at 2393301 extension 208; e-mail pharmacy.enforcement@moh.gov.bn; visit the Section on the first floor of the Department of Pharmaceutical Services Building, Kg Madaras, Mukim Gadong A; or call the Talian Darussalam 123.

Raja Penawar Resdung

Xuandi
-E N D-
Reference : KK/JDP/PR 3/2